Hls Therapeutics — FY2020 Earnings Presentation

6 slides from Hls Therapeutics's earnings presentation, Mar 18, 2021

Slide 1: Q4 & F2020 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2020 Results Conference Call March 18, 2021 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Vascepa: prescription momentum growing
Vascepa: prescription momentum growing… 400 Weekly script data since launch 350 300 … despite a constrained environment Prescriptions 250 • Patient interactions with their doctor primarily virtual during 200 Q4 ‘20 and Q1 ‘21 lockdowns* 150 • Patient visits 30-35% lower vs the fall* 100 • >85% of in
Slide 4: Vascepa Recent Analogues: two-year comparison
Vascepa Recent Analogues: two-year comparison 70K Patients at 60K Peak Number of Prescriptions The oral anti-coagulant market is a relevant analogue 50K for Vascepa. It has a similar market size potential and overlap of healthcare practitioners Vascepa 130-150K (projection) (projected) 40K 30K Eliqu
Slide 5: Q4 & F2020 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2020 Results Conference Call March 18, 2021 TSX - HLS
Slide 6: Q&A
Q&A TSX - HLS